ITGB5: A Potential Drug Target for Cancer and Autoimmune Diseases

Target Name: ITGB5

NCBI ID: G3693

ITGB5

ITGB5: A Potential Drug Target for Cancer and Autoimmune Diseases

ITGB5, also known as integrin subunit beta 5, is a protein that is expressed in many different tissues throughout the body. It is a key component of integrin, a protein that is found on the surface of many different cell types and plays a role in cell-cell adhesion.

Recent studies have identified ITGB5 as a potential drug target and have shown that blocking ITGB5 can lead to a range of potential therapeutic benefits.

One of the main reasons for the interest in ITGB5 as a drug target is its role in cancer progression. ITGB5 has been shown to be highly expressed in many different types of cancer, including breast, ovarian, and prostate cancer. Additionally, studies have shown that blocking ITGB5 can lead to a reduction in cancer cell proliferation and the formation of new blood vessels, which can be a deadly combination for cancer cells.

Another potential therapeutic benefit of ITGB5 is its role in autoimmune diseases. ITGB5 has been shown to be involved in the development and progression of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. By blocking ITGB5, researchers hope to be able to treat these diseases and improve the quality of life for patients.

In addition to its potential role in cancer and autoimmune diseases, ITGB5 has also been shown to be involved in the regulation of cell signaling pathways. Studies have shown that ITGB5 can interact with a variety of signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. By interfering with these pathways, ITGB5 has the potential to contribute to a range of different diseases.

Despite the potential benefits of ITGB5 as a drug target, there are also concerns about its potential drawbacks. For example, ITGB5 has been shown to be involved in the regulation of cell adhesion, which could make it a useful target for drugs that are currently used to treat cell-cell adhesion disorders. Additionally, ITGB5 has been shown to be involved in the regulation of the cytoskeleton, which could make it a potential target for drugs that are used to treat cytoskeletal disorders.

Overall, ITGB5 is a protein that has the potential to be a drug target or biomarker for a range of different diseases. Further research is needed to fully understand its role and to develop safe and effective treatments.

Protein Name: Integrin Subunit Beta 5

Functions: Integrin alpha-V/beta-5 (ITGAV:ITGB5) is a receptor for fibronectin. It recognizes the sequence R-G-D in its ligand

The "ITGB5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGB5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets